MA
KZR

MYDA Advisors’s Kezar Life Sciences KZR Stock Holding History

MYDA Advisors’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,751
Closed -$110K – 150
2019
Q4 		$110K Buy
+2,751
New +$84.7K 0.05% 105
2018
Q3 		– Sell
-1,230
Closed -$213K – 161
2018
Q2 		$213K Buy
+1,230
New +$215K 0.09% 120

Other funds holding KZR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MYDA Advisors's KZR Position: Q1 2020 in Review

MYDA Advisors sold out of Kezar Life Sciences (KZR) in Q1 2020, closing a stake of 2,751 shares — an estimated $110K sold.

MYDA Advisors first reported a position in KZR in Q2 2018 and held it in 2 quarters. The position peaked at $213K in Q2 2018. 59 funds tracked by Wall St. Rank hold KZR as of Q1 2020.

  • MYDA Advisors reported no remaining Kezar Life Sciences position as of Q1 2020 after selling out during the quarter.
  • MYDA Advisors sold 2,751 Kezar Life Sciences shares in Q1 2020, an estimated $110K.
  • MYDA Advisors first reported a position in Kezar Life Sciences in Q2 2018 and held it in 2 quarters.
  • MYDA Advisors's Kezar Life Sciences position peaked at $213K in Q2 2018.
  • 59 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2020.

Based on MYDA Advisors's 13F filing for Q1 2020, filed 14 May 2020.